

## Phase II Study of Myeloablative 8/8- or 7/8-Matched Allogeneic Transplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Najla El Jurdi<sup>1\*</sup>, Alex Hoover<sup>2\*</sup>, Daniel O'Leary<sup>1\*</sup>, Qing Cao<sup>3</sup>, Ashish Gupta<sup>4</sup>, Christen Ebens<sup>4</sup>, Joseph Maakaron<sup>1</sup>, Brian C. Betts<sup>1</sup>, Armin Rashidi<sup>1</sup>, Mark Juckett<sup>1</sup>, Troy Lund<sup>4</sup>, Veronika Bachanova<sup>1</sup>, Margaret MacMillan<sup>4</sup>, Jeffrey Miller<sup>1</sup>, Paul Orchard<sup>4</sup>, John Wagner<sup>4</sup>, Gregory Vercellotti<sup>1</sup>, Daniel Weisdorf<sup>1</sup>, Kathryn Dusenbery<sup>5</sup>, Stephanie Terezakis<sup>5</sup>, Shernan Holtan<sup>1</sup>

\*Authors Contributed Equally

<sup>1</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

<sup>2</sup>Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA

<sup>3</sup>Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

<sup>4</sup>Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, USA

<sup>5</sup>Department of Radiation Oncology, University of Minnesota, Minneapolis, MN

### ABSTRACT

**Introduction:** Graft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac) and mycophenolate mofetil (MMF) would reduce the incidence of GVHD in patients receiving a matched or single antigen mismatched HCT without an increase in risk of malignant relapse.

**Methods:** This is a phase II study conducted at the University of Minnesota using a myeloablative regimen of either: (A) total body irradiation (TBI, total dose 1320 cGy, administered in 165 cGy fractions, twice a day from days -4 to -1) or (B) Busulfan 3.2mg/kg daily (cumulative AUC 19,000 – 21,000  $\mu\text{mol}/\text{min}/\text{L}$ ) plus fludarabine 160mg/m<sup>2</sup> days -5 to -2, followed by a GVHD prophylaxis regimen of PTCy (50mg/kg days +3 and +4), Tac and MMF (beginning day +5). The primary endpoint is cumulative incidence of chronic GVHD requiring systemic immunosuppression at 1-year post-transplant. We compared results to our previous myeloablative protocol for matched donors utilizing cyclosporine/methotrexate (CSA/MTX) GVHD prophylaxis.

**Results:** From March 2018 - June 2022, we enrolled and treated 125 pediatric and adult patients with a median follow up of 472 days. Grade II-IV acute GVHD occurred in 16% (95% confidence interval (CI): 9-23%); Grade III-IV acute GVHD was 4% (CI: 0-8%). No patients experienced grade IV GVHD, and there were no deaths due to GVHD before day 100. Only 3 developed chronic GVHD requiring immune suppression, (4%, CI: 0-8%). Two-year overall survival (OS) was 80% (CI: 69-87%), and (graft-versus-host disease-free, relapse-free survival) GRFS 57% (CI: 45-67%), both higher than historical CSA/MTX. The incidence of grade II-IV aGVHD, cGVHD, and NRM were all lower with PTCy/Tac/MMF compared to historical CSA/MTX. One-quarter (25%) experienced relapse (CI: 15-36%) similar to historical CSA/MTX. There was no statistically significant difference in survival outcomes between recipients of matched versus 7/8 donors.

**Conclusion:** Myeloablative HCT with PTCy/Tac/MMF results in extremely low incidence of severe acute or chronic GVHD, the primary endpoint of this clinical trial. Relapse risk is not increased compared to our historical CSA/MTX cohort.

## Introduction

Graft-versus-host disease (GVHD) has been the major complication limiting success of allogeneic hematopoietic cell transplantation since the field began 70 years ago. The standard regimen to prevent GVHD, a combination of calcineurin inhibitor and methotrexate, has been used since the 1980s, but it has significant tissue toxicity and does not decrease the risk of chronic GVHD (reviewed in <sup>1</sup>). The drug abatacept was approved by the FDA for the prevention of acute GVHD in 2021, however it also does not address the risk of chronic GVHD. <sup>2</sup> Intensifying broad immunosuppression using ATG or other agents may decrease the occurrence of GVHD but simultaneously increase the risk of relapse or infections with no overall net benefit. <sup>3,4</sup> Post-transplant cyclophosphamide-based regimens are increasingly being tested for GVHD control, with an evolved understanding of its mechanism of action including restraint of alloreactive conventional T cell proliferation function with preferential recovery of regulatory T cells. <sup>5,6</sup> In a single center, prospective phase II study, we examined the hypothesis that using the regimen of PTCy, tacrolimus (Tac), and mycophenolate mofetil (MMF) would lower the incidence of both acute and chronic GVHD without increasing the risk of relapse. We compared the results of this regimen to a historical group of allogeneic hematopoietic cell transplant recipients who received well-matched allografts and myeloablative conditioning (MAC) with cyclosporine and methotrexate (CSA/MTX) prophylaxis at our institution to understand the differences in GVHD, relapse, and survival outcomes with PTCy/Tac/MMF compared to our historical standard.

## Methods

This is an analysis of a phase II study at the University of Minnesota using a MAC regimen of either: 1. total body irradiation (TBI, total dose 1320 cGy administered twice a day from days -4 to -1) or 2. Busulfan 3.2mg/kg daily (cumulative AUC 19,000 – 21,000  $\mu\text{mol}/\text{min}/\text{L}$ ) plus fludarabine 160mg/m<sup>2</sup> days -5 to -2 for patients unable to receive radiation, followed by a GVHD prophylaxis regimen of PTCy (50mg/kg days +3 and +4), Tac and MMF (both beginning day +5). The primary endpoint was cumulative incidence of chronic GVHD requiring systemic immunosuppressive treatment (IST) at 1-year post-transplant. This clinical trial is registered at ClinicalTrials.gov under NCT03314974. Eligibility included age  $\leq$  60 years, hematologic malignancy with candidacy for allotransplantation, matched related donor (MRD) or unrelated (URD) donor with either a bone marrow (BM) or filgrastim-mobilized peripheral blood (PB) graft. This trial was a prospective clinical trial reviewed and approved by the Masonic Cancer Center Protocol Review Committee and Human Subjects Institutional Review Board at the University of Minnesota. All patients signed Institutional Review Board–approved informed consent in accordance with the Declaration of Helsinki.

We compared the results from the current study to our previous MAC protocol which utilized a regimen of either cyclophosphamide (60mg/kg days -6 and -5)/TBI (1320 cGy administered twice a day from days -4 to -1) or busulfan (0.8 mg/kg/dose IV in 4 daily doses days -9 to -6 [total 12.8 mg/kg])/ cyclophosphamide (50 mg/kg days -5 to -2), with GVHD prophylaxis utilizing cyclosporine and methotrexate. The historical comparison cohort was also a prospective phase II clinical trial registered under NCT00176930. Patients underwent allogeneic HCT on this clinical trial between 2005 – 2018. Eligibility criteria regarding organ function and hematologic malignancy status were the same for each study, although the upper age limit was lower (age 55) for the historical cohort. Disease risk was classified as standard or high risk based on the American Society for Blood and Marrow Transplantation Request for Information 2006 risk scoring schema (<http://www.asbmt.org>).

For analysis of key clinical endpoints, the cumulative incidence estimator was used to calculate the probabilities of acute GVHD, chronic GVHD, relapse or disease progression, and engraftment, reflecting the non-event deaths as a competing risk. <sup>7</sup> Similarly, cumulative incidence was used to estimate transplant related mortality (TRM) treating relapse as a competing risk. Fine and Gray regression analyses was used to compare the differences between cumulative incidence curves. <sup>8</sup> The cut off significance level was 0.05, and all reported P values are two-sided. SAS 9.4 (SAS Institute, Inc., Cary, NC) and R version 4.1.2 (The R Foundation for Statistical computing) were used for all analyses.

## Results

From 2018 - 2022, we treated 125 patients with MAC and PTCy/Tac/MMF prophylaxis, with a median follow up of 472 days post-transplant. Demographics and baseline characteristics of this prospective cohort as well as the historical comparison cohort of patients receiving myeloablative transplantation with CSA/MTX are detailed in Table 1.

**Table 1. Patient baseline characteristics.**

	<b>CSA/MTX Frequency (%)</b>	<b>PTCy/Tac/MMF Frequency (%)</b>
<b>N</b>	344	125
<b>Year of Transplant</b>	2005-2018	2018-2022
<b>Gender: Male</b>	206 (59.9%)	65 (52.0%)
<b>Age: &lt;18</b>	76 (22.1%)	20 (16%)
Median (IQR)	39.6 (26.6)	38.7 (27.5)
<b>Diagnosis</b>		
ALL	85 (24.7%)	38 (30.4%)
AML	122 (35.5%)	55 (44.0%)
CML	29 (8.4%)	87 (6.4%)
Myeloproliferative disease	4 (1.2%)	3 (2.4%)
MDS	30 (8.7%)	9 (7.2%)
Lymphoma	49 (14.2%)	5 (4.0%)
Other Malignant disease	25 (7.3%)	7 (5.6%)
<b>Disease Risk</b>		
Standard	221 (64.2%)	85 (68.0%)
High	123 (35.8%)	40 (32.0%)
<b>Graft Source</b>		
Bone Marrow	101 (29.4%)	43 (34.4%)
Peripheral Blood Stem Cells	243 (70.6%)	82 (65.6%)
<b>Donor Type</b>		
Matched Related Donor	286 (83.1%)	69 (55.2%)
Mismatched Related Donor	15 (4.4%)	0
Matched Unrelated Donor	41 (11.9%)	44 (35.2%)
Mismatched Unrelated Donor	2 (0.6%)	12 (9.6%)
<b>Conditioning</b>		
MA: TBI	317 (92.2%)	112 (89.6%)
MA: Bu/Flu	27 (7.9%)	13 (12.4%)
<b>Lansky/Karnofsky</b>		
<60	1 (0.3%)	1 (0.8%)
70-80	29 (8.4%)	27 (21.6%)
90-100	304 (88.4%)	97 (77.6%)
Missing	10 (2.9%)	0 (0%)
<b>Comorbidity (HCT-CI)</b>		
<4	240 (69.8%)	112 (89.6%)
4+	37 (10.7%)	13 (10.4%)
Missing	67 (19.5%)	0 (0%)

The historical CSA/MTX cohort was similar to the prospective PTCy cohort. Both groups had a slight male predominance (59.9% vs 52% for PTCy), similar proportion of pediatric patients (22.1% vs 16% for PTCy), and similar median age of 39.6 years versus 38.7 years for PTCy. The primary diseases for which transplant was performed were similar except for a slightly higher proportion of patients with lymphoma undergoing HCT with CSA/MTX (14.2% versus 4.0% with PTCy). Disease risk was similar between cohorts (high risk in 35.8% of patients versus 32.0% with PTCy). Graft sources were similar between the cohorts, except the CSA/MTX cohort utilized some mismatched related donors as the graft source (4.4% versus 0% for PTCy), and the PTCy cohort utilized more mismatched unrelated donors (9.6% versus 0.6% for CSA/MTX). Most recipients were conditioned with TBI (92.2% versus 89.6% for PTCy). There was a slightly higher proportion of patients with a performance status 90-100 (88.4% versus 77.6% with PTCy). The median time to neutrophil engraftment was 16 days for both cohorts, achieved in 97% receiving CSA/MTX (range 3-31 days) and 99% receiving PTCy (range 13-30 days). The median time to platelet engraftment was also the same at 26 days in both cohorts, achieved in 85% receiving CSA/MTX (range 0-372 days) and 95% in patients receiving PTCy (range 14-98 days). The median duration of hospitalization was 3 days longer in patients receiving PTCy, 28 days (interquartile range [IQR] 9 days) versus 25 days in patients receiving CSA/MTX (IQR 12 days).

GVHD endpoints are plotted with PTCy in comparison to the historical CSA/MTX population in Figure 1. Regarding the prospective study's primary endpoint, only 3 of 105 patients developed chronic GVHD requiring systemic immune suppression at 1 year, for a cumulative incidence of 4% (CI: 0-8%). The cumulative incidence of Grade II-IV acute GVHD by day +100 was 16% (95% confidence interval (CI): 9-23%); Grade III-IV acute GVHD was 4% (CI: 0-8%). Zero patients experienced grade IV GVHD within 100 days after PTCy. All GVHD outcomes were statistically significantly worse with historical CSA/MTX (Figure 1), including grade II-IV aGVHD at 37% (CI 41-42%), grade III-IV aGVHD at 15% (CI 11-19%), and chronic GVHD requiring immunosuppression at 34% (CI 28-39%).

Non-relapse mortality at 1 year (Figure 2A) was higher with CSA/MTX at 19% (CI 14-23%) than PTCy/Tac/MMF (10%, CI 4-16%,  $p=0.03$ ). The two-year cumulative incidence of relapse was 25% (CI: 15-36%), which did not differ from the historical cohort at 21% (CI 16-26%, Figure 2B). However, with PTCy, we noticed a higher relapse probability in children ages 18 and younger (49%, 95% CI 23-74%) compared to children receiving CSA/MTX (26%, 95% CI 16-37%,  $p=0.03$ ). There was no statistically significant difference in relapse rates with PTCy/Tac/MMF vs CSA/MTX in those over age 18 ( $p=0.99$ ). Two-year OS was better with PTCy/Tac/MMF at 80% (CI: 69-87%) versus 64% (CI 58-69%,  $p<0.01$ , Figure 2C). Two-year GRFS was also better with PTCy/Tac/MMF at 57% (CI: 45-67%) than 25% (CI 20-30%,  $p<0.01$ , Figure 2D) with historical CSA/MTX.

In a multivariate analysis of 2-year OS of the cohorts (Table 2), PTCy/Tac/MMF was associated with an over 50% reduction in the hazard of death. High risk disease was also independently associated with a 52% higher hazard of death compared to those with standard risk disease. Patients over age 40 had an 87% higher hazard of death compared to patients under the age of 18.

**Table 2. Multivariate analysis of 2-year OS.**

Parameter	Group	Hazard Ratio CI 95%	P-value
GVHD Prophylaxis	CSA/MTX	1.00	<0.01
	PTCy/Tac/MMF	0.49 (0.29-0.81)	
Age (y)	<18	1.00	0.06
	18-39	1.49 (0.85-2.63)	
	>=40	1.87 (1.11-3.13)	
Disease Risk	Standard	1.00	0.02
	High	1.52 (1.06-2.18)	

Within the PTCy/Tac/MMF cohort, we performed exploratory analyses and found no difference in overall survival between HLA 7/8 vs 8/8 matches ( $p=0.99$ ), sibling versus unrelated donor graft ( $p=0.33$ ), the use of marrow versus peripheral blood stem cells ( $p=0.79$ ), disease status at transplant, including the presence or absence of measurable residual disease (4 patients with MRD in this cohort,  $p=0.16$ ), or type of conditioning (Bu/Flu vs TBI,  $p=0.21$ ). Causes of death varied by donor source (Supplemental Figure 1). Relapse accounted for the most deaths in sibling transplants (71% of sibling HCT deaths) and the second leading cause of death for unrelated donor transplants (33% of URD HCT deaths). The leading cause of death in unrelated donor transplants was respiratory failure due acute respiratory distress syndrome or idiopathic pneumonia syndrome (44% of URD HCT deaths). Only one death attributed to GVHD occurred in the PTCy cohort in a patient with fatal late-onset stage 4 liver acute GVHD that occurred after tacrolimus taper.

## Discussion

The results of this phase II study show that GVHD prophylaxis with PTCy/Tac/MMF with a well-matched donor and a MAC regimen based on TBI or Busulfan/Fludarabine results in a notably low (4%) incidence of chronic GVHD requiring IST at one year, which was the primary endpoint of the trial. It is noteworthy that this regimen is both feasible and effective for both pediatric and adult patients up to the age of 60. The survival advantage derived from this protocol compared to historical CSA/MTX is attributed to the marked decrease in both severe acute and chronic GVHD without any apparent increase in the risk of relapse in adult patients. However, it must be acknowledged that there was a higher rate of relapse observed in pediatric patients receiving PTCy/Tac/MMF when compared to CSA/MTX, thus a careful consideration of the balance between GVHD risk and relapse risk is advisable in pediatric HCT. While we acknowledge several advancements in supportive care may have contributed to improved survival in patients transplanted in 2018-2022 versus 2005-2018, the differences in GVHD-specific outcomes are striking and likely the primary driver of the results.

PTCy was first developed clinically in the haploidentical setting.<sup>9, 10</sup> Subsequent results have been encouraging in studies of PTCy-based GVHD prophylaxis in the context of well-matched donor MAC allotransplantation. A 3-site prospective study of single-agent PTCy in matched bone marrow transplantation and MAC demonstrated a relatively low grade of grade III-IV aGVHD at 15% and chronic GVHD at 14%, with long-term follow up showing a low global IST burden in recipients of PTCy.<sup>11, 12</sup> A subsequent study to expand these results to the adult peripheral blood stem cell MAC transplant setting found that addition of CSA to PTCy maintained low rates of chronic GVHD requiring IST at 1 year at 16%.<sup>13</sup> Children and young adults also have a notably low rate of chronic GVHD after PTCy, with reported incidence rates as low as 0% after matched transplantation and 5-14% with haploidentical grafts.<sup>14-16</sup> Our observed rates of chronic GVHD requiring IST at 1 year are low at 4% in the overall cohort, which may be owed to a combination of factors, including the use of Tac over CSA, the addition of MMF, and the allowance of bone marrow as a graft source in this protocol. Given the relative ease of procurement of PBSC versus bone marrow, the use of PTCy may markedly reduce the need for bone marrow harvesting in the future.

The regimen of PTCy/Tac/MMF used in this study has recently been proposed as the new standard of care for well-matched reduced intensity peripheral blood stem cell transplants based upon the results of phase III BMT CTN 1703. (Bolaños-Meade et al, NEJM, manuscript accepted). Our observed rates of grade III-IV acute and chronic GVHD requiring IST at 1 year are lower than that of 1703 (6.3% and 12.5% respectively), also likely due to the allowance of children and bone marrow grafts on this protocol. A randomized phase III study similar to BMT CTN 1703 has not yet been completed in the myeloablative setting; BMT CTN 1301 utilized MAC but BM as the graft source and single agent Cy, thus results are not directly comparable.<sup>17</sup> Co-stimulation blockade with abatacept has been studied in the MAC setting, but rates of chronic GVHD remain high at >50%.<sup>2</sup> Thus, a PTCy-based regimen may be preferable to Tac/methotrexate/abatacept in view of lower chronic GVHD risk, although this has not been directly tested in a randomized study.



Prevention of relapse/progression of the underlying disease should likely be the next step in the evolution of PTCy-based platforms. Novel enhancement of natural killer cell function or prevention of T cell exhaustion appears may be promising in the PTCy context.<sup>18</sup> The approach currently under study at the University of Minnesota is addition of an oral aurora kinase A inhibitor to PTCy/sirolimus to preserve generation of antitumor cytotoxic T lymphocytes<sup>19</sup>; GVHD and relapse prevention are dual primary endpoints of this ongoing study (NCT05120570). Shared targets of GVHD and malignancy exist, such as CD83, which could be exploited to control both alloreactivity and enhance GVL in future studies.<sup>20</sup>

In summary, a GVHD prophylaxis regimen of PTCy/Tac/MMF shows significantly better acute and chronic GVHD control, without an increase in relapse risk, compared to historical CSA/MTX in well-matched MAC transplantation. The benefit of GVHD control is highest in adults. Pediatric HCT recipients may require a risk adapted approach to mitigate higher rates of relapse.

### Acknowledgements

This research was supported by NIH grant P30 CA77598 utilizing the Biostatistics Core of the Masonic Cancer Center, University of Minnesota and the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR002494. We would like to acknowledge our excellent team of BMT pharmacists, without whom this study would not be possible.

### Disclosures

- Holtan: *Vitrac Therapeutics*: Research Funding; *Incyte*: Research Funding; *CSL Behring*: Other: Clinical trial adjudication.
- Gupta: *Blue Rock Therapeutics*: Membership on an entity's Board of Directors or advisory committees; *Vertex Pharmaceuticals*: Consultancy.
- Maakaron: *Gilead*: Research Funding; *CRISPR Therapeutics*: Research Funding; *Precision BioSciences*: Research Funding; *Scripps*: Research Funding; *Fate Therapeutics*: Research Funding; *ADC Therapeutics*: Research Funding.
- Betts: *Brian Betts*: Patents & Royalties: WO2019165156; *CTI Biopharma*: Honoraria; *Incyte*: Honoraria.
- Bachanova: *AstraZeneca*: Membership on an entity's Board of Directors or advisory committees; *Incyte*: Research Funding; *FATA Therapeutics*: Research Funding; *ADC Therapeutics*: Membership on an entity's Board of Directors or advisory committees; *Citius Pharma*: Research Funding; *Karyopharma*: Consultancy; *Gamida Cell*: Membership on an entity's Board of Directors or advisory committees, Research Funding.
- Miller: *ONK Therapeutics*: Honoraria, Membership on an entity's Board of Directors or advisory committees; *Vycellix*: Consultancy, Current holder of *stock options* in a privately-held company; *GT Biopharma*: Consultancy, Current holder of *stock options* in a privately-held company, Research Funding; *Fate Therapeutics*: Consultancy, Current holder of *stock options* in a privately-held company, Research Funding.
- Wagner: *ASC Therapeutics*: Consultancy; *Bluebird Bio*: Consultancy; *Vertex Pharmaceuticals*: Consultancy; *Magenta Therapeutics*: Consultancy; *Rocket Pharmaceuticals, Inc.*: Consultancy, Current equity holder in publicly-traded company.
- Vercellotti: *Mitobridge-Astellas*: Research Funding; *Omeros*: Research Funding; *CSL-Behring*: Research Funding.
- Weisdorf: *FATE Therapeutics*: Other: Research Support; *Incyte*: Other: Research support.

## Figure Legends

**Figure 1. GVHD-related outcomes of PTCy/Tac/MMF versus historical CSA/MTX: (A) Acute GVHD grade II-IV, (B) Acute GVHD grade III-IV, and (C) Chronic GVHD requiring systemic immunosuppression.**

**Figure 2. Relapse and survival outcomes of PTCy/Tac/MMF versus historical CSA/MTX: (A) Non-relapse mortality, (B) relapse/progression, (C) overall survival, and (D) graft-versus-host disease-free, relapse-free survival (GRFS).**

**Supplemental Figure 1: Causes of death by donor with PTCy/Tac/MMF GVHD prophylaxis.**



## References

1. Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? *Biol Blood Marrow Transplant.* 2010;16(1 Suppl):S18-27. Epub 20091024. doi: 10.1016/j.bbmt.2009.10.016. PubMed PMID: 19857584; PMCID: PMC2832712.
2. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. *J Clin Oncol.* 2021;39(17):1865-77. Epub 20210115. doi: 10.1200/JCO.20.01086. PubMed PMID: 33449816; PMCID: PMC8260909.
3. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. *J Clin Oncol.* 2017;35(36):4003-11. Epub 20171017. doi: 10.1200/JCO.2017.75.8177. PubMed PMID: 29040031; PMCID: PMC8462523.
4. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A, Messina C, Uderzo C, Ripaldi M, Porta F, Giorgiani G, Giraldi E, Pession A. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. *Blood.* 2000;95(5):1572-9. PubMed PMID: 10688810.
5. Hadjis AD, Nunes NS, Khan SM, Fletcher RE, Pohl AP, Venzon DJ, Eckhaus MA, Kanakry CG. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4(+) T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation. *Front Immunol.* 2022;13:796349. Epub 20220215. doi: 10.3389/fimmu.2022.796349. PubMed PMID: 35242129; PMCID: PMC8886236.
6. Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. *J Clin Invest.* 2019;129(6):2357-73. Epub 20190326. doi: 10.1172/JCI124218. PubMed PMID: 30913039; PMCID: PMC6546453.
7. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. *Stat Med.* 1997;16(8):901-10. doi: 10.1002/(sici)1097-0258(19970430)16:8<901::aid-sim543>3.0.co;2-m. PubMed PMID: 9160487.
8. Fine JP, Grey RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association* 1999;94(446):496-509.
9. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubarb P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. *Biol Blood Marrow Transplant.* 2002;8(7):377-86. doi: 10.1053/bbmt.2002.v8.pm12171484. PubMed PMID: 12171484.



10. Raiola AM, Dominiotto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. *Biol Blood Marrow Transplant*. 2013;19(1):117-22. Epub 20120829. doi: 10.1016/j.bbmt.2012.08.014. PubMed PMID: 22940057.
11. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. *J Clin Oncol*. 2014;32(31):3497-505. Epub 20140929. doi: 10.1200/JCO.2013.54.0625. PubMed PMID: 25267759; PMCID: PMC4209101.
12. Kanakry CG, Bolanos-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. *Blood*. 2017;129(10):1389-93. Epub 20170103. doi: 10.1182/blood-2016-09-737825. PubMed PMID: 28049637; PMCID: PMC5345732.
13. Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. *Blood*. 2016;127(11):1502-8. Epub 20160113. doi: 10.1182/blood-2015-10-672071. PubMed PMID: 26764356; PMCID: PMC4797026.
14. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, Huo J, Cooke KR, Jones R, Fuchs E, Luznik L, Symons HJ. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. *Biol Blood Marrow Transplant*. 2016;22(1):112-8. Epub 20150904. doi: 10.1016/j.bbmt.2015.08.034. PubMed PMID: 26343947; PMCID: PMC4706497.
15. Jaiswal SR, Chakrabarti A, Chatterjee S, Bhargava S, Ray K, O'Donnell P, Chakrabarti S. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. *Biol Blood Marrow Transplant*. 2016;22(3):499-504. Epub 20151121. doi: 10.1016/j.bbmt.2015.11.010. PubMed PMID: 26612281.
16. Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, Klein O, Llosa N, Zambidis ET, Ambinder R, Bolanos-Meade J, Borrello I, Brodsky R, DeZern A, Gojo I, Showel M, Swinnen L, Smith BD, Luznik L, Jones RJ, Fuchs EJ. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. *Blood Adv*. 2020;4(16):3913-25. doi: 10.1182/bloodadvances.2020001648. PubMed PMID: 32813874; PMCID: PMC7448587.
17. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. *J Clin Oncol*. 2022;40(4):356-68. Epub 20211202. doi: 10.1200/JCO.21.02293. PubMed PMID: 34855460; PMCID: PMC8797487.

18. McCurdy SR, Radojcic V, Tsai HL, Vulic A, Thompson E, Ivcevic S, Kanakry CG, Powell JD, Lohman B, Adom D, Paczesny S, Cooke KR, Jones RJ, Varadhan R, Symons HJ, Luznik L. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. *Blood*. 2022;139(4):608-23. doi: 10.1182/blood.2021013054. PubMed PMID: 34657151; PMCID: PMC8796655.
19. Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebt SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. *Sci Transl Med*. 2017;9(372). doi: 10.1126/scitranslmed.aai8269. PubMed PMID: 28077684; PMCID: PMC6368389.
20. Holtan SG, Savid-Frontera C, Walton K, Eaton AA, Demorest C, Hoeschen A, Zhang L, Reid K, Kurian T, Sayegh Z, Julia E, Maakaron J, Bachanova V, El Jurdi N, MacMillan ML, Weisdorf DJ, Felices M, Miller JS, Blazar BR, Davila ML, Betts BC. Human effectors of acute and chronic GVHD overexpress CD83 and predict mortality. *Clin Cancer Res*. 2023. Epub 20230109. doi: 10.1158/1078-0432.CCR-22-2837. PubMed PMID: 36622700.

**A****B****C**